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The outcome of a  virus infection mainly relates to the respective characteris- 
tics of the viruses, the cells they replicate in, and the immune system of the host 
(1-4). The immune response of man is usually analyzed in terms of humoral or 
cellular reactions.  Much data have accumulated on humoral responses to viral 
infections; in fact, a  rise in antibody titer against a  given virus or its antigenic 
components is currently used to identify the agents causing a patient's infection 
(5). Specific anti-viral antibodies are also a major factor in inhibiting the spread 
of viral infection,  resulting  in  the  patient's recovery from a  primary infection 
and the  prevention of reinfection with  the same agent  (6-8).  In vitro,  specific 
antibodies can reduce the infectivity of most viruses that bud from cells' plasma 
membranes  and,  when  fresh  serum  is  added  to  the  culture  as  a  source  of 
complement, can lyse virus-infected cells (9,  10).  In cooperation with lymphoid 
cells  isolated  from  human  peripheral  blood,  anti-viral  antibodies  lyse  virus- 
infected target cells in vitro, although neither reactant alone is lytically efficient 
(11-14). 
Yet, three lines of evidence strongly suggest that cell-mediated immunity is involved 
in  recovery from viral infection  in  man.  First,  delayed-type hypersensitivity  (DTH)  1 
reactions can be generated after many virus infections. Jenner probably observed such a 
reaction  in  a  patient  previously exposed to  cowpox and  variolated  (15). Others  have 
reported DTH reactions in humans infected with a  variety of viruses (16, 17). Second, 
patients with congenital or acquired gamma globulin deficiencies recover normally from 
infections with measles and varicella viruses. In contrast,  children having profound T- 
cell defects associated with thymic lymphopenia or Wiscott-Aldrich syndrome develop 
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major complications  like  giant  cell  pneumonia  and  encephalitis  after  measles  virus 
infection (18-20).  Vaccination of these children with vaccinia virus has led to generalized 
vaccinia infection (21). Third, experiments involving either virus-infected murine target 
cells  mixed with  thymus-derived  (T)  lymphocytes from infected  mice  or  intact  mice 
undergoing  experimental  depletion  and  reconstitution  of T  cells  both  provide  clear 
evidence of a cellular immune defense mechanism against a  variety of virus infections 
like ectromelia, vaccinia, and lymphocytic choriomeningitis (22-24).  Murine cytotoxic T 
cells can also be generated in vitro during a secondary immune response to virus (25). 
Observations  made  in  mice  suggest  directions  for  seeking  T-lymphocyte-mediated 
responses in humans. The time-course of murine T-cell responses is sharply limited after 
primary  infection,  since  the  number  of cytotoxic T  cells  is  maximal  5-7  days  after 
infection and negligible by the 12th day. Moreover, cytotoxic T cells lyse virus-infected 
murine target cells only when both cell types share at least one gene product of the K or D 
region of the major murine histocompatibility (H-2) complex (26, 27). 
With  this  background  information,  we  decided to  investigate  cell-mediated 
cytotoxic responses in humans against virus-infected target cells and determine 
whether this reaction is related to HLA specificities, the human counterpart of 
murine K  and D  specificities. We wanted to see whether a similar time-course to 
raise  cytotoxic  cells  and  a  genetic  restriction  occurred  in  man.  We  chose  to 
immunize  volunteers  with  vaccinia  virus  because  its  effects  are  relatively 
inocuous and recovery is uncomplicated. Further, vaccinia virus, and the closely 
related  ectromelia  virus,  are  known  to  elicit  well-defined  cytotoxic T-cell re- 
sponses with H-2 restriction in mice (22,  27). 
Materials  and  Methods 
Immunization  of Human Subjects.  Nonimmune  (normal)  peripheral blood lymphoid  cells 
were obtained from blood of human volunteers before immunization and from other volunteers 
who were not immunized. Immune cells came from 12 normal adults given vaccinia virus vaccine. 
These included nine males and three females, 21-43 yr of  age, all free  of  skin disease,  allergic 
history,  and ocular  infection.  All subjects  had been vaccinated with vaccinia  virus  during child- 
hood,  and  two  had  been  revaccinated  2  or  more  years  before  this  study.  For  this  study,  each  subject 
underwent a 2 cm  2  scarification  with  smallpox vaccine (Lederle  Laboratories,  Pearl River,  N. Y.) 
in the area of  the left  deltoid  muscle, and 36-48 h later  induration and redness developed with 
resolution  within 7-10 days.  Vesicles and regional adenopathy appeared by 72 h. No adverse 
reactions  due  to  vaccination  occurred.  For  most subjects,  30-50 ml of  blood was obtained from  the 
antecubital  vein on the day  of  vaccination  (day 0)  and on  days 1,  3, 5,  7, and 12 after  vaccination; 
others  gave blood on days 0, 6, 7, 8, and 21. Drawn blood was transferred  sterily  to 50-ml plastic 
tubes containing heparin (20  U heparin/ml blood). 
Peripheral  Blood  Lymphocytes (PBL).  Peripheral  blood  lymphomonocytes were  obtained after 
Ficoll-Hypaque gradients (28).  Monocytes  were removed  by  adherence  to  plastic  dishes  after  i  h at 
37°C in 5% CO2. As tested  by eosin uptake, more than 95% of  monocytes were removed by this 
procedure. PBL were separated into  T cells  and T-depleted PBL by using  the ability  of  T cells  to 
make rosettes  with sheep erythrocytes (SRBC) treated with neuraminidase (13,  29).  In most 
experiments the T cells  in the pellet  obtained from the Ficoll-Hypaque gradient were carefully 
resuspended with 5-10 ml of  medium [RPMI 1640 + 20% fetal  calf  serum (FCS)],  and the T-cell 
rosettes  were rerun through a second Ficoll-Hypaque gradient.  T cells  were freed  from SRBC by 
warming resuspended cells  at 37°C for 20 rain,  shaking vigorously,  and reapplying to a Ficoll- 
Hypaque gradient  or  by lysis  of  the SRBC after  briefly  resuspending  the  pellet  in  a low ionic  acid 
solution [1/3  Eagle's  minimal essential  medium  (MEM) and 2/3 distilled  water] followed by 
addition  of  MEM  containing 10% FCS and sodium bicarbonate.  In  both  cases  T cells  were washed 
twice  after  manipulation. The T-cell  population recovered  was  greater  than  98% pure  on  the  basis 
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as tested by immunofluorescence (less than one cell positive per 200) using polyvalent fluorescein- 
ated goat anti-human IgG. 
In some experiments the PBL were segregated into populations  of Fc receptor-positive and 
negative cells by using ox erythrocytes (ORBC) treated with a subagglutinating dose of rabbit IgG 
antisera to ORBC (EA) (30). In brief, 5 x  106 PBL in RPMI 1640 supplemented with 10% FCS were 
incubated at a ratio of 1:25 with EA for 5 rain at room temperature and spun at 1,000 rpm for 10 
rain in an International PR2 centrifuge. After an incubation of 30 rain at room temperature and 
gentle resuspension, the mixture was layered on the top of a Ficoll-Hypaque gradient and spun for 
15 rain at 2,200 rpm using an International PR-2 centrifuge (Damon Int. Equip. Corp., Needham 
Heights,  Mass.).  Fc.negative PBL at the interface were collected, washed twice, counted,  and 
resuspended at the desired concentration.  Fc-positive cells were found in the pellet, resuspended 
in  the  same  medium,  and  rerun  through  a  Ficoll-Hypaque gradient,  after  which  the  ORBC 
were lysed by treatment with the low ionic acid solution. The lymphoid cells were pelleted and 
resuspended  in  MEM  supplemented  with  10%  FCS and  bicarbonate.  ARer 60  min  incubation 
at room temperature,  lymphoid cells were  washed twice and  resuspended  at the desired con- 
centration.  The subpopulations  of Fc-positive and negative cells were each more than 95% pure 
as judged by reresetting with EA. In various experiments the percent of Fc-positive cells in PBL 
varied from 21  to  40%. The T-cell  and  T-depleted populations described  above were also  segregated 
into  Fc-positive  and negative cells  with the above method. 
Virus.  The WR strain  ofvaccinia virus originally  passed in L 929  cells  was a gift  from Dr. W. 
K. Joklik, Duke University, Durham, N. C. This virus was used to infect  HeLa cells  grown in 
suspension in 2,000-mi flasks  containing 400 ml of  Spinner's medium supplemented by 10% FCS, 
2% glutamine,  and antibiotics (penicillin,  75 U/ml; streptomycin, 75 ~g/ml). The cells  were 
infected  at a multiplicity  of  infection  (MOI) of  0.5-1.  Supernatant fluid  was removed after  48 h, 
and  vaccinia  virus  was isolated  from  the  cells,  sonicated,  and  banded in a sucrose density gradient 
(31).  The virus  pool  used  titered  2.5 × 109  plaque-forming units (PFU)/ml on Vero cells  (32).  Wild- 
type Edmousten measles virus was obtained from the American Type Culture Collection,  Rock- 
ville,  Md. and passed on HeLa cells  (33). 
Cell  Lines.  Skin flbroblasts  were obtained from biopsies  taken at the forearms of  eight of  the 
vaccinated volunteers,  and processed as  previously described (13).  HeLa cells  were obtained from 
Eric Stanbridge, Department of Microbiology, University of  California Medical School, Irvine, 
Calif. and were devoid of mycoplasma contamination.  Another line  of HeLa cells  persistently 
infected with measles virus was raised as previously described (33).  The Vero cells  (monkey 
kidney) and the mouse cell  line L  929 were initially  obtained from Flow Laboratories, Inc., 
Rockville,  Md. and propagated in our laboratory.  All four  cell  lines  were grown as monolayers in 
75  cm  s  Falcon  plastic  flasks  at  37°C in  a moist  atmosphere containing 5% COs. The growth medium 
consisted of MEM  supplemented with 10% FCS heated at 56°C for 30 rain,  bicarbonate, I% 
glutamine, and antibiotics  (penicillin,  75 U/ml; streptomycin, 75 ~g/ml). 
HLA Determination.  HLA determinations on human PBL and on HeLa cells  were performed 
in the laboratory of  Paul Terasaki, UCLA  Medical School, Los Angeles, Calif.,  and by Michele 
Pellegrino,  Department of Molecular Immunology, Scripps Clinic and Research Foundation, La 
Jolla,  Calif. 
Antisera,  Purification  of Human  Ig  and  of Fab's  Fragments  from  Rabbit  Anti-Human 
IgG.  Human IgG obtained from Pentex Inc., Kankakee, Ill. was chromatographed through a DEAE- 
cellulose column equilibrated with 0.175 M phosphate-buffered saline (PBS), pH 7.8 (13). Rabbits 
were immunized at 3-wk intervals with Img of this IgG in Freund's complete adjuvant for the first 
inoculation, while all subsequent immunizations were done with Freund's incomplete adjuvant. 
After 3 mo of immunization, rabbits were bled several times, and sera containing more than i mg 
of specific antibody against human IgG/ml were pooled. In order to purify the Fab'~ fragment from 
this anti-human  IgG, 250 ml of the rabbit-pooled antisera heated for 45 rain at 56°C was passed 
through a 100 ml Sepharese 6B column to which more than 200 mg of human IgG had been coupled 
(34). After extensive washing with 1 M NaC1, and 20% sucrose in 0.1 M NaC1, specific rabbit IgG 
against  human  IgG was eluted with  1 M  acetic acid in 0.5  M NaC1,  neutralized immediately, 
concentrated,  digested  with  pepsin  (14),  and  rechromatographed  through  a  Sephadex  G-200 
column. Fab's from normal rabbit IgG was purified by chromatography through a DEAE-cellulose 
column equilibrated with 0.175  M PBS, pH 7.2,  and digested with pepsin  (13). To obtain rabbit 
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5 × 10  ~  PFU of  vaccinia  virus  at  1-wk intervals  for  a month and  then  bled.  The resulting  antisera 
were  heat  inactivated  (56°C,  45  min).  The  IgG  fraction  was  purified  by  DEAE-cellulose  chromatog- 
raphy, absorbed on HeLa cell  monolayers,  and conjugated with fluorescein  isothiocyanate as 
reported (10). 
Rabbit ORBC  antiserum was raised  by immunizing rabbits  with increasing amounts of 10% 
ORBC  in PBS (0.5-3  ml) twice weekly for  a month. The hemagglutinating titer  of  the IgG anti- 
ORBC  and its  specificity  were determined by published immunochemical tests  (30). 
Human IgG  was purified  from  three  human sera  harvested from  the  volunteers  before  vaccina- 
tion  with vaccinia virus (M. O.) and 15 days after  vaccination (M. O. and J. H.).  The purified 
fractions (10 mg/ml PBS) were shown to be free  of contaminants by both Ouchterlony and 
immunoelectrophoresis analyses.  IgG from a subject  (M. O.) who was immune to vaccinia  virus 
was absorbed  by incubating 3 ml of  10  mg immune IgG/ml PBS for  I  h at  37°C and  then for  2 h at 
4°C with  a confluent  monolayer  of  L 929  cells  grown in  a T75 Falcon  flask  (Falcon  Plastics,  Div.  of 
BioQuest, Oxnard, Calif.)  and previously infected  with vaccinia virus.  The procedure was re- 
peated twice,  and a control  was established  by absorbing 3 ml of  the same IgG preparation with 
uninfected  L 929 monolayers. The IgG  preparations  were  centrifuged  for  i  h at  40,000  rpm using  a 
SW40 rotor  in  a L 65 ultracentrifuge  (Beckman Instruments, Inc.,  Fullerton,  Calif.)  to  eliminate 
IgG aggregates,  cell  debris,  virus-antibody  complexes, and free  vaccinia  virus. 
Detection  of Viral Antigens  on Cells.  Living fibroblasts  infected  with vaccinia  virus  and 
uninfected  were assayed for  the presence of  surface  viral  antigens by direct  immunofluorescence 
using fluoresceinated  rabbit  IgG anti-vaccinia  virus.  Procedures, equipment used,  and cell  han- 
dling  have been described (33).  Similar procedures and equipment were used for  the detection  of 
membrane-bound immunoglobulins on lymphocytes. 
Cytolytie 5~Cr-Release Assay.  Targets included human fibroblasts,  HeLa, or  L 929 cells.  Cells 
were grown as monolayers in Falcon T75 plastic  flasks,  trypsinized,  washed twice in growth 
medium, and dispersed  in  solution.  100-~I  samples  containing 1-2 x 104  cells  and  4/~Ci  5~Cr  were 
added  to  each  well  of  6  mm flat-bottomed  Falcon  TC 3040  microtest  plates.  After 10  h incubation  at 
37°C a confluent  monolayer  containing I x 104  or  2 × 104  fibroblasts  and  2 × 104  HeLa or  L 929  cells 
formed. The monolayers  were then  washed  twice  and  incubated with  either  50/~l  of  growth media 
containing  4-8 × 104  PFU ofvaccinia  or  50 btl  of  growth  media  for  4  h. After  an additional  wash the 
medium was removed and one drop (30 ~l)  of  growth medium was added  to each  well followed  by 
the  addition  of  immune reagents  or  growth  medium. When anti-vaccinia  antibodies  or  rabbit  Fab's 
anti-human IgG and lymphocytes were used simultaneously, a measured amount of  antibody  or 
rabbit  Fab'2  diluted  in  100  ~I  of  growth  media  was added  first  and  allowed  to  react  with  the target 
cells  for  30  min before  the  addition  of  lymphocytes  in  100  ~l  volume. The  final  volume  was  adjusted 
to  350/~l  by  the  addition  of  growth medium. When cells  infected  with  measles  virus  were used,  the 
cells  were labeled with 5~Cr  (4 ~Ci/well) for 2 h and washed twice.  Then the target  cells  were 
infected  at a MOI of  3, incubated overnight, and finally  washed twice before  use. 
The addition  of  350 ~I of  water  and 5 pl of  5% Nonidet  P-40 (NP-40) (used  as maximal release) 
released 80-90% of  the total  radioactivity.  100-pI  samples were removed at 6 and/or 18 h and 
counted  in  tubes in  a Searle Automatic Gamma  Counter (Searle  Analytic Inc.,  Des Plaines,  Ill.). 
All the determinations were run at least  in triplicate.  Variability  between triplicate  samples 
never  exceeded 10% and averaged  4% of  the total  sample count.  The percent of  5~Cr  released  was 
calculated  according  to  the  following  formula: [(E-S)/(MAX-S)] × 100,  where E is  the  s~Cr  released 
from infected  target cells  in the presence of  PBL and anti-viral  antibody (13,  35);  S is the 5~Cr 
released  from infected  or uninfected cells  in medium or in the presence of  anti-viral  antibody or 
other  reagents but  in  the  absence  of  PBL (the  higher  value  was  used  for  calculations);  and  MAX  is 
the  total  51Cr  released  from  infected  target  cells  upon  addition  of  water  and  NP-40.  s~Cr  release  was 
calculated  separately in each condition for beth infected  and uninfected cells,  and the release 
induced by PBL or lymphocyte subpopulations from uninfected  target  cells  was subtracted from 
the values obtained with infected  target  cells. 
Results 
Preliminary Experiments.  To determine optimal conditions for virus expres- 
sion on the cell surface, human fibroblasts of different HLA specificities were 
infected  with  vaccinia  virus  at  MOIs  of 0.1,  1,  2,  4,  8,  and  16.  The  living L.  H.  PERRIN,  R.  M.  ZINKERNAGEL,  AND  M.  B.  A.  OLDSTONE  953 
fibroblasts,  harvested and incubated with fluoresceinated rabbit  antibody to 
vaccinia virus, expressed viral antigens on their surface by 1 h  after infection, 
and by 4 h more than 95% of  the fibroblasts were strongly positive when infected 
at an MOI of 2 or greater. 4 h  after infection with an MOI of 0.1,  results were 
inconsistent with between 1 and 10% of cells expressing viral antigens on their 
surfaces, whereas at an MOI of 1 approximately 50% of the cells were positive 
(42, 51, and 59% in three different experiments). Uninfected fibroblasts did not 
express vaccinia virus antigens. HeLa and murine L 929 cells responded to this 
infection similar to the fibroblasts. 
To obtain the most accurate measurements of cell lysis, three different fibro- 
blast lines at varying concentrations were settled into fiat-bottomed wells and 
labeled 12 h later with 51Cr. Vaccinia virus was added at MOIs of 2, 4, 8, and 16, 
and the spontaneous release for virus-infected and uninfected cells was deter- 
mined. In an 18 h assay, it was found that the spontaneous release was minimal 
at MOIs of 2 or 4 (22 _+ 3.4%, 24.5 _+ 4.1%, and 21.3 _+ 2.1%, respectively, for the 
three different infected target cells at a MOI of  4) and that between 0.5  × 104 and 
4 ×  104 target cells per well functioned adequately. Spontaneous release of 51Cr 
from uninfected and virus-infected cells was approximately the same. In subse- 
quent experiments the number of  fibroblasts used was 1-2 × 104 per well and the 
MOI 4. 
Reports conflict as to whether normal human PBL lyse autologous or homolo- 
gous human skin fibroblasts (36, 37). Therefore, we initially studied the activity 
of PBL  and T  or  T-depleted  (PBL depleted of SRBC-rosetting lymphocytes) 
lymphocyte subpopulations from three individuals before vaccination against 
autologous or homologous fibroblasts infected or not with vaccinia at different 
lymphocyte to target cell ratios. As seen in Table I, all PBL populations lysed 
both autologous and homologous fibroblasts, infected or not, at a  25:1 lympho- 
cyte to target cell ratio. On occasion, greater lytic activity was detected against 
uninfected fibroblasts than against infected cells (data not shown). Fig. i  shows 
that lysis of uninfected fibroblasts was minimal with T  cells  and with PBL 
depleted of Fc receptor-bearing cells.  (Similar results were obtained with in- 
fected fibroblasts and PBL from persons who were not revaccinated.) In con- 
trast, lysis was maximal with T-depleted lymphocytes (Fig. 1). In all results the 
amount of immune specific 51Cr release was subsequently expressed after sub- 
traction of the value obtained on uninfected fibroblasts. 
Cytotoxicity Induced by PBL after Vaccinia Virus Revaccination 
TIME-COURSE AND EFFECT OF LYMPHOCYTE TO TARGET RATIO IN AN AUTOLOGOUS 
SYSTEM.  Fig. 2 shows the percentage of  S~Cr specifically released from vaccinia- 
infected autologous fibroblasts by immune PBL from three  volunteers.  PBL 
were harvested from the donors at various intervals after vaccination and added 
to fibroblasts, which were then assayed for 51Cr release over several time points. 
~Cr release was usually maximal around day 7 and decreased markedly by day 
11.  Immune PBL of five other  vaccinated individuals, not shown,  produced 
similar degrees of cytotoxicity with similar time-courses and kinetics. PBL of 
three individuals were also assayed 21  and 30 days after vaccination, and the 
specific 5~Cr release from infected target cells was always less than 10%  at a 
lymphocyte target cell ratio of 25:1. Generally, 5~Cr release was not increased at 954  IMMUNE  LYSIS  OF  VACCINIA-INFECTED  TARGETS  IN  MAN 
TABLe.  I 
Lysis of Human Fibroblasts Infected with Vaccinia Virus by Different PBL Populations 
Obtained from Nonrevaccinated Humans* 
% Specific slCr release from human fibroblast from 
donor (HLA-A/B): 
Donor  L.P.  (1, -/8, 37)  M.O.  (2,  26/12,  38)  M.D. (2, 3/7, 17) 
In-  Unin-  In-  Unin-  In-  Unin- 
fected  fectod  fected  fectod  fected  fected 
L. P.  Total PBL (1, -/8, 37)  27~  28  25  26  28  29 
T cells  20  21  22  19  21  23 
T-depleted PBL  32  31  29  29  32  33 
S. O.  Total PBL (2,26/12, 38)  26  27  24  26  27  29 
T cells  20  18  23  20  21  23 
T-depletedPBL  29  28  29  30  31  33 
M.D.  Total PBL (2, 3•7,  17)  30  31  27  29  31  32 
T cells  22  21  22  21  21  22 
T-depleted PBL  35  33  30  31  35  35 
Spontaneous release  18  17  20  18  19  18 
* Total PBL, T, and T-depleted PBL (total  PBL depleted of  lymphocytos which rosette with SRBC 
treated with neuraminidase)  from nonrevaccinated  subjects were added to virus-infected or 
uninfected fibroblasts at an effector to target  cell ratio of 25:1. Amount  of 51Cr specifically 
released after  18 h incubation was determined (see  Materials and Methods). 
Number  reflects  the s'Cr released without correction as a mean of  triplicate  determinations. The 
standard error of  the mean (SEM) did not exceed 6%. 
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FIG.  I.  Total PBL, T cells,  T-depleted PBL, and PBL depleted of lymphocytes bearing Fc 
receptors  from  a nonrevaccinated  subject  were  added to uninfected  autologous  (a) or 
homologous  (b) fibroblasts at different effector to target cell ratios. The amount of 51Cr 
released was determined after 18 h incubation, calculated as described in the Materials and 
Methods, and expressed as the mean of  triplicate  determinations -+ SEM. Similar values (not 
reported) were obtained by using infected fibroblasts as targets and the same lymphocyte 
population.  Spontaneous  release  was 23  -+ 3%  for fibroblasts in (a) and  20  -+ 5%  for 
fibroblasts in (b). L.  H. 
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FIG.  2.  Three donors' total PBL harvested at different days after vaccination with vacci- 
nia virus were tested against autologous fibroblasts infected or not with vaccinia virus at an 
effector to  target ratio  of 25:1.  The amount of 51Cr released was determined after 18  h 
incubation, calculated as described in the Materials and Methods, and expressed in the 
figure for infected fibroblasts after subtraction of  values obtained for uninfected fibroblasts. 
(Mean of triplicate determination _+  SEM.) Spontaneous release for uninfected fibroblasts 
was between 18 and 25%, while for infected fibroblasts it was between 19 and 26%. 
955 
day 7 as compared to day 0 when PBL were added to uninfected fibroblasts, but 
when enhanced, this increase never exceeded 7% of the total SlCr release. 
CYTOTOXICITY  INDUCED  BY  PBL  IN  AUTOLOGOUS,  HOMOLOGOUS,  OR  HETEROLO- 
GOUS COMBINATIONS.  Immune PBL from 10 donors of known HLA specificities 
were tested 7 days after vaccination against a panel offibroblasts of  known HLA 
specificities and against murine L 929 cells. There was no relationship between 
the homology of HLA antigens of PBL and infected target cells and the ability of 
immune PBL to lyse vaccinia-infected target cells in 9 of 10 individuals tested 
(Table II). The one exception was J. H. (Table II, Fig. 3 c ), whose PBL lysed his 
own fibroblasts and two other fibroblast lines which shared one or two HLA 
specificities with his  PBL.  In contrast his PBL did not lyse a  third infected 
fibroblast line devoid of common HLA determinants. Table II shows also that 
PBL from the  three  vaccinated females  (L.  E.,  P.  B.,  and T.  T.)  were  less 
cytotoxic for virus-infected targets (always less than 25% at 12.5:1 ratio) than 
PBL from males. This occurred despite the similarity in response to vaccination 
by females and males. 
Not only did autologous effector and target cell combinations show similar 
cytolytic activity to  homologous combinations, but  immune  PBL  also  lysed 
heterologous L 929 virus-infected cells (Table II). To exclude the possibility that 
this response was quantitative rather than qualitative, different PBL to target 
ratios were used in systems sharing or not sharing HLA determinants and in 
heterologous systems using mouse L 929 target cells. As seen in Fig. 3, homology 
in HLA antigens between PBL and the virus-infected target cells for individuals 
R. Z.  (Fig. 3a) and L. P.  (Fig. 3b) bears no direct relationship to the degree of 
lysis measured. Yet, for J. H. (Fig. 3c) a quantitative effect occurred; at a high 
lymphocyte to target cell ratio (20:1), target cells with or without HLA antigens 
in common with the PBL were lysed to similar degrees, but at lower ratios (5:1) a 
restriction was seen. PBL from R. Z. (Fig. 3a) and L. P.  (Fig. 3b) lysed L 929 
cells and human fibroblasts with a similar efficiency; unfortunately, there were 
insufficient PBL from J.  H. (Fig. 3 c) to test against L 929 targets. 
CELL POPULATIONS INVOLVED IN  THE  CYTOTOXIC  ACTIVITY.  Since the killing 
of virus-infected cells by human immune PBL did not usually require sharing of 956  IMMUNE  LYSIS  OF  VACCINIA-INFECTED  TARGETS  IN  MAN 
TABLE II 
Relationships  between HLA Determinants on PBL and Those Expressed on Vaccinia Virus- 
Infected Targets during Immune Specific Lysis* 
% Specific S~Cr release from infected human fibroblasts from donors (HLA-A/B) 
Mouse 
Donors  HLA type  J.H. (2,  M.O.  M.B. (9, 
L. P. (1,  R.Z. (2,  T.T. (3,  C. C. (2,  L-929 
28/12,  (2, 26/  11/35, 
-/8, 37)  3/35,  8)  10/7,  -)  28/7,  14) 
14)  12, 38)  -) 
J. H.  2, 28/12,  14  42.3~:  3.5 
L.  P.  1, -/8, 37  45.0  30.5 
R.Z.  2, 3/35,  8  25.8  27.9  38.1  19.3 
T.T.  3, 10/7,  -  17.8  13.9  22.9 
M. O.  2, 26/12,  38  35.5  42.1 
M.B.  9, 11/35,  -  30.2  38.3 
M.  D.  2, 3/7,  17  32.6  39.8  39.5  26.8 
F. T.  25, 28/12, 39  6.9  11.3  16.5  14.3 
L.  E.  30, 33/14,  13  3.9  7.8  3.2  -3.0 
P. B.  3, -/7, 5  21.2  7.6 
39.0  18 
74.0  51.0 
28.7  25.8  55.6 
23.4 
33.2  37.4  35.5 
37.3  32.9  36.3 
41.5  32.6  23.0 
13.9  17.5 
4.3 
22.9  16.3 
*  PBL harvested 7 days after vaccination with vaccinia virus were mixed with vaceinia-infected or uninfected fibroblasts of different HLA 
specificities or with murine L 929 cells at an effector to target cell ratio of 12.5:1 for 18 h. Tests were run in triplicate, and the SEM did not 
exceed 6%. Experiments were done on different days and the spontaneous release varied from 17 to 29% for uninfected fibroblasts and from 
19 to 32% for infected fibroblasts.  Within each experiment the spontaneous  release was similar among the various fibroblast targets. 
Spontaneous release for uninfected and infected L 929 cells was between 17 and 26%. 
Number refers to the mean value of the specific S'Cr released from infected cells. Autologous combinations are underlined. 
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FIG.  3.  Three  donors' total  PBL harvested  7 days after vaccination with vaccinia virus 
were tested against autelogous and homologous  fibroblasts as well as routine L 929 cells 
infected or not with vaccinia virus at different effector to target cell ratio. Condition of the 
5~Cr assay  and  calculations  are  the  same  as  described  in  Fig.  2.  HLA  specificities  are 
indicated in the figure and shared HLA specificities between donor PBL and target cells are 
underlined. (a) R. Z., (b) L. P., and (c) J. H. Spontaneous release of the various targets was 
the same as described in Table II. 
HLA markers between lymphocytes and infected targets,  we sought to identify 
the killer  cells.  Whole  PBL,  T-cell,  and  non-T-cell  subpopulations  separately 
were assayed against autologous, homologous, and heterologous virus-infected 
target cells. As seen in Fig. 4, the T-depleted subpopulation usually showed one- 
half to two times greater specific lysis of virus-infected cells than did the total 
PBL population and was efficient against autologous (Fig. 4a) and homologous 
(Figs. 4 b and c) infected targets. In contrast, T cells caused only limited specific 
lysis that was also unrelated to homology of HLA antigens between T lympho- 
cytes and target cells. Lo  Ho  R.  M.  ZINKERNAGEL,  AND  M.  B.  A.  OLDSTONE  PE RRIN, 
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Fro.  4.  Two  donors' total  PBL,  T  cells,  and T-depleted cells  harvested  7  days  after 
vaccination with vaccinia virus were tested against autologous (a) and homologous (b and 
c) targets. Conditions of the 51Cr assay and calculations are the same as described in Fig. 2. 
Spontaneous release was 18 and 24% for (a), 17 and 25% for (b) and (c) for uninfected and 
infected fibroblasts, respectively. Donor PBL: (a and b) L. P.; (c) M. D. 
TABLE  III 
Immune Lysis of Vaccinia Virus-Infected Target Cells by Different Lymphocyte 
Populations After Vaccination with Vaccinia Virus* 
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% Specific 51Cr release from infected human fibroblasts by 
donor PBL harvested at: 
Do-  Lymphocyte popu- 
nors  lations  Day 5  Day 6  Day 7 
Autol-  Homol-  Autol-  Homol-  Autol-  Homol- 
ogous  ogons  ogous  ogous  ogous  ogous 
L.  P, 
T, W. 
Total PBL (1, -/8, 37)  65  7  23  19  45  30 
T  8  3  5  4  4  5 
T-depleted PBL  6  7  55  32  67  36 
Total PBL (3, 10/7, -)  6  6  21  25  23  24 
T  5  3  5  5  6  3 
T-depleted PBL  7  7  37  42  39  45 
* PBL autologous or homologous to vaccinia virus-infected fibroblasts were harvested 5, 6, and 7 
days after vaccination. Total PBL, T, or T-depleted subpopulations  were added to virus-infected 
or uninfected fibroblasts at an effector to target cell ratio of 12.5:1 for 18 h. Tests were run in 
triplicate and the  SEM  did not exceed  6%.  Spontaneous release of uninfected and infected 
fibroblasts was between 17 and 22%. 
5 Number refers to the average value of the specific 51Cr released. 
Since in prior experiments (not shown), autologous infected fibroblasts were 
sometimes lysed to a  greater extent than homologous fibroblasts and L 929 cells 
at day 5, we examined the possibility that the early immune response involves a 
different mechanism and/or a  different cell population. However, this is not the 
case. Table III shows that specific 5~Cr lysis of fibroblasts infected with vaccinia 
virus by autologous or homologous immune  PBL, T  cells, and T-depleted PBL 
occurs at days 5,  6,  and 7 with the same pattern. 
Macrophages  and  monocytes  are  not  a  prerequisite  for  the  lytic  activity 
detected, since all PBL, T cells, and T-depleted PBL had been depleted of plastic- 
adherent  cells.  Moreover,  in other  experiments, three  donors'  PBL,  whether 958  IMMUNE  LYSIS  OF  VACCINIA-INFECTED  TARGETS  IN  MAN 
TABLE  IV 
Role of Fc Receptor-Bearing PBL on the Lysis of Human Fibroblasts Infected with 
Vaccinia Virus* 
Donors  Lymphocyte populations 
% 5~Cr release from infected human fi- 
broblasts 
Lymphocytes depleted of Fc+ bearing 
cells: 
No  Yes 
K. P. (not done) 
T. T.  (3, 10/7, -) 
M.  B.  (9,  11/35,  -) 
Total PBL  23 +- 4  5 _+ 35 
T  6+-2  6_+2 
T-depleted PBL  39 +- 6  8 +- 3 
Total PBL  23 +- 5  4 _+ 2 
T  4_+3  4_+2 
T-depleted PBL  39 _+ 5  6 _+ 3 
Total PBL  32 -+ 5  4 +- 3 
T  5_+3  4_+1 
T-depleted PBL  47  _+ 6  7 _+ 3 
* PBL obtained 7 days after vaccination were separated into total PBL, T, or non-T subpopula- 
tions. Various lymphocyte populations were depleted of Fc receptor-bearing IgG cells by reset- 
ting with ORBC-IgG (see Materials and Methods). Lymphocyte populations with and without Fc 
receptor-bearing cells were added to vaccinia virus-infected or uninfected fibroblasts at a ratio of 
12.5:1 for 18 h. Subject two was tested on autelogous targets, whereas subjects one and three 
were assayed on homologous test systems. Assays were run in triplicate. Numbers represent the 
mean specific 51Cr release _+ SEM. Spontaneous release of uninfected and infected target cells 
was less than 23%. 
$ When Fc receptor-bearing PBL purified from total PBL were tested against the same infected 
target cells at a ratio of 12.5:1, they induced a specific 51Cr release of 15 _+ 3% (K. P.), 14 _+ 4% (T. 
T.), and 17 _+ 5% (M. B.). 
depleted of adherent  cells or not, lysed similar amounts  of autologous fibroblasts 
infected  with  vaccinia  7  days  after  the  donor's  vaccination  (less  than  10% 
variation  at 25:1  PBL:target  ratio). 
Depletion of Fc receptor-bearing lymphocytes from the total immune  PBL or 
from non-T-cell subpopulations  harvested  7 days after vaccination almost com- 
pletely abrogated the cytolytic potential of both populations (Table IV and Fig. 
5).  Yet,  when  Fc  receptor-positive  lymphocytes  were  added  to  virus-infected 
targets,  minimal  amounts  of immune  specific lysis occurred,  suggesting either 
that  a  second  factor  or  a  second  cell population  was  required  or that  the  Fc 
receptors  were  blocked  by  immune  complexes  (rabbit  IgG  anti-ORBC-ORBC 
antigens). 
Suppressor T  cells may modulate the response of cytotoxic T  cells. In humans, 
T cells bearing Fc receptors for IgG can act as suppressor T cells in some systems 
(38). 2 Total T-cell populations or T-cell subpopulations depleted of cells bearing 
Fc receptors for IgG caused minimal  or no killing of virus-infected target  cells 
(Table IV). In contrast, when we depleted T  cells bearing Fc receptors for IgG in 
a  known  suppressor system, the expected suppression was lost. 2 
20ldstone, M. B. A., A. Tishon, and L. Moretta. 1977. Maternal-fetal interrelationships: active 
thymus derived suppressor lymphocytes are found in human cord blood. Nature (Lond.). In press. L.  H.  PERRIN,  R.  M.  ZINKERNAGEL,  AND  M.  B.  A.  OLDSTONE 
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Fro.  5.  Two donors' total PBL (0--0  and A--A) and total PBL depleted of Fc receptor- 
bearing lymphocytes (Q---O and /X---/X) harvested 7 days after vaccination with vaccinia 
virus were tested against human fibroblasts infected or not with vaccinia virus at different 
effector to target cell ratios. Conditions of the 5~Cr assay and calculations are the same as 
described in  Fig.  2.  Spontaneous release was  19%  for uninfected and  21%  for infected 
fibroblasts. 
Inhibition of Lysis of Vaccinia-Infected  Fibroblasts.  When the FAB'~ frag- 
ment of rabbit anti-human IgG antisera was added in varying amounts to virus- 
infected target cells before the addition of immune PBL, immune specific lysis 
decreased more than 95% at 6 ~g/ml of the Fab'2 preparation  (Fig. 6). Lysis of 
uninfected fibroblasts only partially  decreased when Fab'2 rabbit anti-human 
IgG was added.  Rabbit Fab'2 without antibodies to human  IgG did not block 
immune specific lysis of infected fibroblasts. In other experiments with immune 
PBL from two additional donors, Fab'2 anti-human IgG at a concentration of 25 
~g/ml similarly abrogated specific lysis of vaccinia virus-infected fibroblasts by 
more than 95% (ratio 10 PBL:I target cell). 
Specificity  of Lysis.  Human  fibroblasts were infected either  with  measles 
virus or vaccinia virus and used as targets to assess the specificity of lysis by 
immune PBL (Table V).  Measles virus-infected fibroblasts were lysed equiva- 
lently  by  PBL  harvested  at  days  0  and  7,  whereas  vaccinia  virus-infected 
fibroblasts  showed a  marked  increase  in  51Cr release  when  mixed  with  PBL 
taken  at  day  7  compared  to  PBL  obtained  at  day  0.  In  other  experiments 
measles-infected fibroblasts were lysed specifically by PBL obtained from chil- 
dren 7 days after vaccination with live attenuated measles virus (L. Perrin,  D. 
Reynolds, and M. B. A. Oldstone,  unpublished observation). 
Antibody-Dependent Cell Cytotoxicity  (ADCC) in the Vaccinia System.  The 
above experiments  implicate non-T cells with Fc receptors taken from donors 
recently vaccinated with vaccinia virus as the responsible immune killer cell. 
This  suggests  that  ADCC  might  be  the  mechanism  by which  the  vaccinia- 
infected target cells are lysed. Therefore, the ability of nonimmune PBL to lyse 
vaccinia-infected target cells upon addition of specific antibodies against vacci- 
nia virus was studied.  Human IgG preparations  purified from the sera of two 
individuals 15 days after revaccination and one of these two individuals before 960  IMMUNE  LYSIS OF  VACCINIA-INFECTED TARGETS  IN  MAN 
100- 
75- 
~  5O- 
e~ 
~  25, 
~g  of  RFab'  2 aHulg/ml 
FIG.  6.  Different amounts of specific rabbit (R) Fab'2 anti-human IgG (aHuIg) were added 
to human fibroblasts infected or not with vaccinia virus before addition of PBL harvested 
from two individuals 7 days after vaccination with vaccinia virus. Results are expressed as 
percent of inhibition of lysis obtained in the absence of rabbit Fab'~ anti-human IgG [42% for 
donor I  (M.  B.) (D--Q) and 26% for donor 2 (T. T.) (Q---O)]. The effector to target ratio was 
25:1. Conditions of the s~Cr assay and calculations are the same as described in Fig.  2. 
Spontaneous release was between 21 and 24% for uninfected and infected fibroblasts. 
TABL~  V 
Specificity of Vaccinia-Immune PBL as Tested on Human Fibroblasts Infected with 
Vaccinia or Measles Virus* 
Donors  % Specifc 51Cr release from targets infected with: 
Vaccinia virus  Measles virus 
Day 05  Day 7  Day 0  Day 7 
R. Z.  (2,  3/35,  8)  -2  -+  3  55  _+  6  10  +_  3  12  +_  3 
T.T. (3,  10/7, -)  -6+- 2  26_+  3  5_+  2  4+_  2 
M.  B.  (9,  11/35,  -)  1  -+ 3  41  _+  4  23  _+  5  26  -+ 5 
Spontaneous release  16-21§  16-20  17-23  19-23 
* PBL harvested just before vaccination (day 0) and 7 days after vaccination were added either to 
vaccinia or measles virus-infected or uninfected target cells at a ratio of 25:1 for 18 h. All three 
PBL-target systems were autologous and each sample was run in triplicate. Number represents 
the mean specific 5~Cr release _+  SEM. 
Day of vaccinia virus vaccination. 
§ Experiment for each individual was done at a different time. Range of values for spontaneous 
release of slCr from target cells during test periods. 
revaccination were tested for their ability to lyse target cells infected or not with 
vaccinia  virus  in  the  presence  of nonimmune  PBL.  None  of the  three  IgG 
preparations  enhanced  lysis  of uninfected  target  cells.  In  contrast,  both  the 
postvaccination IgG preparations and to a  lesser extent the prevaccination IgG 
preparation over a  wide range of concentrations significantly enhanced lysis of 
vaccinia-infected target  cells  (Fig.  7).  When  absorbed  on  monolayers of L  929 
cells infected with vaccinia virus, the activity of a  postvaccination IgG prepara- L.  H.  PERRIN,  R.  M.  ZINKERNAGEL,  AND  M.  B.  A.  OLDSTONE  ,o] 
30-  ~ 
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Final Concentration of  IgG Added in/pg 
Fro.  7.  Three IgG preparations [(A--A), J. H.; (O-.-©), MO after revaccination; (O-nO), 
MO before  vaccination] were incubated for 30 min with fibroblasts infected or not with 
vaccinia virus, before  addition of PBL  of a  nonrevaccinated individual. The effecter  to 
target cell ratio was 25:1, and the 51Cr assay read at 6 h. Calculations were the same as 
described in Fig. 2. The spontaneous release was 9% for uninfected and 10% for infected 
fibroblasts. 
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tion decreased by more than 90%  (31-2% specific 51Cr release,  0.5 mg/ml  IgG, 
and PBL:target cell ratio of 25:1 in a 6 h assay). Absorption on uninfected L 929 
cells had no significant effect (21-18%). 
Next, varying PBL to target cell ratios and varying concentrations of immune 
IgG were studied in  the  ADCC  assay.  Fig.  8 shows the effect of varying the 
PBL:target cell ratios.  Maximum lysis occurred using immune IgG at 1 mg/ml 
and a  PBL:target cell ratio of 50:1. At a ratio of 25:1 (ratio used in the previous 
experiments),  the killing of PBL harvested from eight nonrevaccinated donors 
in the presence and absence of added anti-vaccinia antibody was studied. Table 
VI shows that specific 51Cr release was marked at 6 h,  increased at 18 h  when 
specific anti-vaccinia  antibodies  and nonimmune  PBL were added to infected 
target  cells.  This  antibody-dependent  lysis  equalled  that  caused  by immune 
PBL 7 days after vaccination in the absence of added antibodies (Tables II and 
V).  We also noted that HeLa cells were more readily lysed than human fibro- 
blasts. 
To learn whether cytophilic antibodies act as inducers of lysis in the presence 
of PBL, immune PBL from three individuals bled 7 days after vaccination were 
treated with trypsin (2.5 mg/ml in MEM at 37°C for 30 min) to remove their IgG, 
washed twice with  complete  media,  incubated  at  room temperature  for 3  h, 
washed again, and tested in parallel with untreated immune PBL. Less than 2% 
immunoglobulin-positive lymphocytes could be detected on the PBL treated by 
trypsin when tested by direct fluorescence using a polyvalent goat anti-human 
immunoglobulin serum. Lysis by PBL treated with trypsin was not significantly 
reduced  in two preparations  [before/after treatment  % specific 51Cr release  _+ 962  IMMUNE  LYSIS  OF  VACCINIA-INFECTED  TARGETS  IN  MAN 
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FIG. 8.  Total PBL  from two individuals not revaccinated:  (A---/x,  ©-.-©) were added at 
different effector  to target ratio to fibroblasts infected or not with vaccinia virus after a 
previous incubation of the target with 100 /~I of a solution containing  1 mg/ml  of anti- 
vaccinia antibodies. (A---A) represents the killing  of  infected target cells  by PBL from donor 
(A---A) in the presence of the same antibody to vaccinia virus previously absorbed with 
vaccinia-infected L 929 cells  (see Materials and Methods). Conditions and calculation as if 
the 51Cr assay were the same as in Fig. 7. The spontaneous release was 10% for uninfected 
and 11% for infected fibroblasts. 
TABLE  VI 
Specific Antibodies to Vaccinia Virus and Nonimmune PBL 
Lyse Vaccinia Virus-Infected Cells* 
% Specific 51Cr release from infected cells 
Donors  HeLa cells at: 
Hu fibroblasts at 6 h 
6h  18h 
1  32-+ 5  40-+ 5  46-+ 7 
2  20-+ 4  37-  4  45-+ 8 
3  15-+ 3  24-  6  32-+ 3 
4  24-+ 6  34-+  7  57-+ 5 
5  12-+ 2  27-+ 3  35-+ 3 
6  18-+ 5  28-+ 3  37-+6 
7  9-+7  18-+2  22-+5 
8  24-+ 5  36-+ 3  53  -+ 4 
Specific 5'Cr release induced by PBL from eight individuals not revac- 
cinated combined with human antibodies against vaccinia virus. As- 
say was run for 6 h or 18 h and the spontaneous release was 8 -+ 3% for 
human fibroblasts infected for 6 h  and 9  -+  3% and 20  +  5%,  respec- 
tively, for HeLa cells infected with vaccinia virus. Specific antibodies 
did not enhance the 5'Cr release observed in their absence. Lympho- 
cytes induced a release varying from 5 to 9.5% at 6 h for both infected 
fibroblasts and HeLa cells, 11-22% at 18 h  from infected HeLa cells, 
and 8-20% from uninfected HeLa cells. These values were subtracted 
from the values obtained upon addition of anti-vaccinia antibodies to 
PBL.  Results are expressed as the mean of triplicate determination 
-+SEM. L.  H.  PERRIN,  R.  M.  ZINKERNAGEL,  AND  M.  B.  A.  OLDSTONE  963 
SEM: 39 _+ 5% vs. 35 -+ 6% (donor M. B.), 45 _+ 4% vs. 36 _+ 5% (donor R. Z.)], and 
reduced 50% in the third  [42  _+ 6% vs. 21  _+ 7% (donor M. O.)]. 
Discussion 
This investigation was undertaken for two purposes. First we wished to follow 
the  reactivity  of PBL  from  humans  vaccinated  with  vaccinia  virus  against 
vaccinia-infected human fibroblasts.  For ethical reasons, only individuals who 
had been previously vaccinated during their childhood were revaccinated and 
all except one developed local induration suggestive of DTH reactions.  Second, 
we wished to study T-cell cytotoxic killing in humans and determine whether an 
HLA restriction  governs killing of virus-infected target by the host's lympho- 
cytes as H-2 restricts the vaccinia virus T-cell cytotoxicity in the mouse model 
(26,  27). 
A good immune-specific cytotoxic activity against vaccinia-infected cells was 
detected in PBL by day 5 after vaccination, peaked by days 7-8, and subsided by 
day 12. There were only weak suggestions of participation of cytotoxic T cells. 
First, in only 1 of 12 individuals studied was there restricted lyric activity of PBL 
for  fibroblasts  sharing  common  HLA-A  or  B  determinants.  Second,  a  few 
individuals' PBL lysed more autologous than homologous virus-infected target 
cells. In contrast, the results indicate that non-T cytotoxic lymphocytes bearing 
Fc receptors  and  acting  in  the  presence  of specific antibodies  are  primarily 
responsible for the lysis of virus-infected target cells. 
PBLs from 11 of the 12 individuals newly vaccinated with vaccinia virus lysed 
fibroblasts infected with vaccinia virus.  The lytic activity with one exception 
was not limited to autologous fibroblasts since homologous fibroblasts with or 
without HLA antigens of the A and B loci shared by the immune PBL, as well as 
murine  L 929 cells, were also lysed. Thus,  histocompatibility between effector 
and target cells did not seem to be necessary for lysis. These results appear to 
contrast with experiments reported in the mice whose spleen cells must share at 
least one gene product of the K  or D  region of the H-2 complex with the virus- 
infected target cell if the latter is to be lysed. However, since the major effector 
cells  in  human  PBL  after  vaccination  are  non-T  cells  and  they require  the 
participation of antibodies, HLA restriction may not be expected. Other consid- 
erations  are that  the  HLA system may be far more polymorphic and present 
more cross-reactivity than the H-2 system (39). Also, the HLA antigens are not 
completely defined; for example, we do not know the HLA determinants of the C 
locus. 
The  probability  that  a  non-T  cell  was  the  cytotoxic cell  in  our  system  is 
supported  in  several  ways.  First,  fractionation  of human  PBL  localized  the 
cytolytic activity in the non-T-cell population.  Second, removal of Fc receptor- 
bearing cells from PBL, T-cell, or T-depleted cell populations abolished cytolytic 
activity. Third,  T  cells alone could not lyse vaccinia-infected target cells even 
after the removal of putative T-suppressor cells. If present, blastlike cytotoxic T 
cells are likely in the T-enriched population, as T blasts rosette with SRBC (40). 
While removal of lymphocytes bearing Fc receptors abolished the lytic activity, 
any Fc receptor-bearing T cells by analogy with the murine T cells, are probably 
not cytotoxic T cells (41). 964  IMMUNE  LYSIS  OF  VACCINIA-INFECTED  TARGETS  IN  MAN 
Two points  clearly emphasize  both the  specificity of the  lysis for vaccinia- 
infected target cells and the development of an active immune response. First, 
immune PBL induced lysis of vaccinia-infected target cells only 5-7 days after 
vaccination.  Second, cytotoxic activity was increased against vaccinia-infected 
cells, but not against measles-infected cells, by PBL harvested at 7 days after 
vaccination as compared to PBL harvested at the day before vaccination (day 0). 
Similar  specificity was observed when PBL obtained 7 days after vaccination 
with  measles  virus,  significantly  enhanced  killing  of measles  virus  but  not 
vaccinia  virus-infected  target  cells  (L.  Perrin,  D.  Reynolds,  and  M.  B.  A. 
Oldstone,  unpublished  observations).  In contrast,  others  showed that  nonim- 
mune PBL naturally lyse human fibroblasts infected with cytomegalovirus (42) 
and postulated that this cytolysis could be directed against an early alteration of 
cell membranes commonly found on several types of human-transformed cells or 
cells infected with herpes virus (43-45). 
The specificity of the lytic process in our system probably emanated from an 
ADCC process. The effector cell seemed to be a K cell, based on three findings. 
First,  lytic activity was associated with the non-T-cell  subpopulation;  second, 
lysis was abolished by removal of Fc receptor-bearing cells from either PBL or 
non-T  cells;  and  third,  Fab'2  fraction  of rabbit  anti-human  IgG  selectively 
inhibited the lysis of human fibroblasts infected with vaccinia virus by immune 
PBL.  Such inhibition  has been demonstrated in other K-cell systems (46,  47), 
probably because the Fc sites of the bound anti-viral antibody were covered or 
altered by anti-Fc antibodies. 
The  anti-viral  antibodies  needed  for lysis  in  this  system could have  been 
carried on the surfaces of the lymphocytes. Alternatively, a more likely hypoth- 
esis is that these antibodies could have been formed and released in culture by 
antibody-producing cells, since trypsin treatment of the immune lymphocytes to 
remove  IgG  from  their  surfaces  did  not  reproducibly  suppress  cytolysis.  If 
plasma cells secreting specific antibodies are generated after vaccination,  this 
phenomenon would be also transient  and could explain the course of the cyto- 
lytic activity detected (peak at day 7 and marked decrease at day 11). Moreover, 
Fc-positive cells without added antibodies showed less activity than the non-T- 
cell population,  suggesting that a  second factor was involved in this reaction. 
Alternatively,  the  activity  of Fc-positive  cells  could  have  been  blocked  by 
immune complexes (rabbit anti-ORBC-ORBC). Experiments are in progress to 
clarify these points. 
That  ADCC  could be an  efficient mechanism  for in  vitro  lysis of vaccinia- 
infected cells was shown by incubating target cells infected with vaccinia virus 
with human anti-vaccinia antibodies, then adding PBL from eight individuals 
who had not been revaccinated. None of these PBL lysed more vaccinia-infected 
target  cells than  uninfected  target  cells unless  anti-vaccinia  antibodies  were 
added to the reaction. Furthermore, the activity of the immune IgG preparation 
could be absorbed with vaccinia-infected but not with uninfected L 929 cells. 
Why are we unable to demonstrate cytotoxic T cells in humans after vaccinia 
virus inoculation, whereas this virus easily raises cytotoxic T cells in mice? The 
existence of a  K-cell-like mechanism need not exclude T-cell killing although 
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vaccinia virus produced only low antibody titers  in our system, this is an 
unlikely explanation.  Could the secondary response we are studying favor 
ADCC  or complement-mediated antibody lysis  of infected cells  instead of the 
expected  T-cell-mediated lysis?  Again, this  is  unlikely,  since  in  mice the  second- 
ary response against vaccinia virus raises  a good T-cell  response (L. Perrin and 
R. M. Zinkernagel, unpublished observations) (25). Perhaps only immature 
cytotoxic T cells  are present in human  PBL  and prolonged contact with the 
infected cells  is required to assure their maturation and transformation into 
cytotoxic  T cells.  This explanation also  seems improbable since vaccinia virus 
replicates in lymphocytes, fulfilling  the requirement for contact during their 
stay in lymph nodes or spleen. Moreover, if  this  hypothesis is true,  cytotoxic  T 
cells  would not limit  the spread of  vaccinia virus infection  since  during the 18 h 
or more of  contact (duration of  the 51Cr  test)  with the infected  cells  to develop a 
lyric  potential,  the infected  cells  would have already generated infectious  virus 
and their  destruction would be without biological  significance.  Perhaps cyto- 
toxic T  cells are trapped in the lesion containing infected cells  expressing 
vaccinia virus antigen and, therefore,  are  barely detectable in  peripheral blood. 
However, we recently found that peripheral lymphocytes of  mice infected  with 
vaccinia virus are as efficient  as spleen cells  in killing  vaccinia-infected  target 
cells,  that T cells  are involved in this  cytotoxic  process and that they are H-2 
restricted.  3 
Perhaps the most reasonable explanation is  that  humans are vaccinated with 
less  than 102 PFU, whereas mice are injected  with 10  ~  PFU. Furthermore, the 
routes of immunization are different:  scarification  vs. intravenous injection. 
Humans  undergo only a local  reaction such as adenopathy, but mice, due to 
their size  and the route of immunization, usually experience general involve- 
ment of  the immune  system. Whether or not a low antigenic stimulus and a 
compartmentalization of  the immune response in man could lead to a modula- 
tion of  the immune response and preferential  production of  specific  antibodies 
instead of  generation of  cytetoxic  T lymphocytes remains to be determined. In 
order to test  this  hypothesis we plan to test  immune lymphocytes from humans 
with systemic virus infection.  Alternatively, Fc-bearing killer  cells  may be a 
subpopulation of  T cells  or  man may respond in a way different  than the  mouse. 
Regardless of the explanation, our data clearly show that aider  humans  are 
vaccinated with vaccinia virus,  "classic"  cytotoxic  T cells  are not readily found 
in the peripheral blood and that effective  and efficient  killing  of  virus-infected 
targets occurs by PBL bearing Fc receptors,  probably in the presence of  plasma 
cells  releasing anti-viral  antibodies. 
Again our  data  raise  the question  of  the  respective  importance ofhumoral and 
cellular  immunity in  protection and the recovery from viral  infection  in vivo.  In 
vaccinia-infected  mice either  the injection  of  immune antibodies or  the transfer 
of  immune spleen T cells  protect  nonimmune mice from a lethal  challenge with 
vaccinia virus (22,  23, 51).  Also, in mice, neutralizing antibody and cytotoxic  T 
cells  appear at a similar time after  infection.  However, cytotoxic  T cells  appear 
to  peak earlier  and have been shown to  possess anti-viral  activity  (21,  27,  52, 53). 
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These  adoptive  transfer  models may not adequately  reflect events  occurring 
during a primary or secondary vaccinia infection. The available data for murine 
vaccinia and  ectromelia infections is compatible with  the  interpretation  that 
cytotoxic T  cells  are  likely  mainly  involved  in  the  early  stages  of primary 
infection whereas antibodies function later and in protection against secondary 
infections. In man, ADCC is demonstrated in many viral and tumoral systems; 
however, it has been difficult to find it in similar systems in mice. In contrast, 
the reverse has been observed for cytotoxic T cells. Whether or not this is related 
to the  experimental  conditions  used or to the  respective importance  of these 
different effector mechanisms  in man  and in mice remains  to be determined. 
One of the major biological functions attributed to cytotoxic T cells is the lysis of 
the virus-infected cells before virus assembly of the virus progeny; such an effect 
has been demonstrated in mice (52, 53) for specific cytotoxic T cells. Similarly, in 
humans,  PBL  in  the  presence  of specific  antibodies  can  lyse  herpes  virus- 
infected target  cells before assembly of viral  progeny  (54).  We have recently 
made  similar  observations using  measles virus and  have further  shown that 
ADCC was efficient long before antibody-mediated complement-dependent lysis 
of the  infected  target  cells  occurred. 3 Therefore,  ADCC  may  be  an  efficient 
mechanism  in  humans  in  restricting  the  spread  of virus  infection,  and  we 
suggest  that  ADCC  probably plays  an  important  role  in  virus  infections  of 
humans. 
Summary 
After vaccinia virus vaccination of human volunteers, local indurations devel- 
oped  within  10  days,  and  regional  adenopathy  was  detected  in  half of the 
individuals.  Their  peripheral  blood lymphocytes (PBL) harvested at different 
days after vaccination showed specific activity against target cells infected with 
vaccinia virus with  a  peak  activity at  day 7.  The  specificity of the  cytotoxic 
activity was not related to HLA markers,  since autologous,  homologous,  and 
heterologous  infected  target  cells  were  lysed  with  the  same  efficiency.  The 
cytotoxic activity was caused by PBL that did not rosette with sheep erythro- 
cytes and could be depleted by more than 90% by removing Fc receptor-bearing 
cells.  T-cell-depleted PBL showed a  one-half to two times greater cytotoxicity 
than  intact  PBL. The cytotoxic activity could also be abrogated by more than 
95% by rabbit Fab's anti-human IgG. On the other hand, nonimmune PBL lysed 
vaccinia-infected  target  cells  in  the  presence  of specific  antibodies  against 
vaccinia  virus,  thus  demonstrating  that  ADCC  could  be  efficient  in  lysing 
vaccinia-infected  target  cells.  We  conclude  that  after  vaccination,  antibody- 
forming cells arise and provide specific anti-viral antibody and that the cytotoxic 
cells  detected  in  this  reaction  are  K  cells.  These  experiments  suggest  that 
antibody-dependent cell cytotoxicity may be of major importance in the recovery 
of man to virus infections. 
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